Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medicinal Chemistry"
DOI: 10.1021/acs.jmedchem.2c00404
Abstract: The U.S. FDA approval of PAXLOVID, a combination therapy of nirmatrelvir and ritonavir has significantly boosted our morale in fighting the COVID-19 pandemic. Nirmatrelvir is an inhibitor of the main protease (MPro) of SARS-CoV-2. Since… read more here.
Keywords: structural insights; nirmatrelvir; evasion nirmatrelvir; sars cov ... See more keywords